C
Corinne Haioun
Researcher at Paris 12 Val de Marne University
Publications - 485
Citations - 32057
Corinne Haioun is an academic researcher from Paris 12 Val de Marne University. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Lymphoma. The author has an hindex of 86, co-authored 451 publications receiving 28435 citations. Previous affiliations of Corinne Haioun include University of Modena and Reggio Emilia & Centre hospitalier universitaire Henri-Mondor.
Papers
More filters
Journal ArticleDOI
Follicular lymphoma international prognostic index.
Philippe Solal-Celigny,Pascal Roy,Philippe Colombat,J. M. White,James Olen Armitage,Reyes Arranz-Saez,Wing Yan Au,Monica Bellei,Pauline Brice,Dolores Caballero,Bertrand Coiffier,Eulogio Conde-Garcia,Chantal Doyen,Massimo Federico,Richard I. Fisher,Javier García-Conde,Cesare Guglielmi,Anton Hagenbeek,Corinne Haioun,Michael LeBlanc,Andrew Lister,Armando López-Guillermo,Peter McLaughlin,Noel Milpied,Pierre Morel,Nicolas Mounier,Stephen J. Proctor,Ama Z. S. Rohatiner,Paul Smith,Pierre Soubeyran,Hervé Tilly,Umberto Vitolo,Pier Luigi Zinzani,Emanuele Zucca,Emili Montserrat +34 more
TL;DR: The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide to help provide an optimal treatment option for patients with follicular lymphoma.
Journal ArticleDOI
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
Andreas Rosenwald,George E. Wright,Karen Leroy,Xin-You Yu,Philippe Gaulard,Randy D. Gascoyne,Wing C. Chan,Tong Zhao,Corinne Haioun,Timothy C. Greiner,Dennis D. Weisenburger,James C. Lynch,Julie M. Vose,James O. Armitage,Erlend B. Smeland,Stein Kvaløy,Harald Holte,Jan Delabie,Elias Campo,Emili Montserrat,Armando López-Guillermo,German Ott,H. Konrad Muller-Hermelink,Joseph M. Connors,Rita M. Braziel,Thomas M. Grogan,Thomas M. Grogan,Richard I. Fisher,Richard I. Fisher,Thomas P. Miller,Thomas P. Miller,Michael LeBlanc,Michael LeBlanc,Michael Chiorazzi,Hong-Bo Zhao,Liming Yang,John Powell,Wyndham H. Wilson,Elaine S. Jaffe,Richard Simon,Richard D. Klausner,Louis M. Staudt +41 more
TL;DR: Gene expression profiling strongly supported a relationship between PMBL and Hodgkin lymphoma: over one third of the genes that were more highly expressed in PMBL than in other DLBCLs were also characteristically expressed in Hodgkinymphoma cells.
Journal ArticleDOI
Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study
B. Coiffier,Corinne Haioun,Nicolas Ketterer,Andreas Engert,H. Tilly,David D.F. Ma,Peter Johnson,Andrew Lister,M. Feuring Buske,John Radford,R. Capdeville,Volker Diehl,Felix Reyes +12 more
TL;DR: In this first trial of rituximab in DLCL and MCL, patients experienced a significant clinical activity with a low toxicity and should be tested in combination with chemotherapy in such patients.
Journal ArticleDOI
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Gilles Salles,John F. Seymour,Fritz Offner,Armando López-Guillermo,David Belada,Luc Xerri,Pierre Feugier,Reda Bouabdallah,John Catalano,Pauline Brice,Dolores Caballero,Corinne Haioun,Lars Moller Pedersen,Alain Delmer,David Simpson,Sirpa Leppä,Pierre Soubeyran,Anton Hagenbeek,Olivier Casasnovas,Tanin Intragumtornchai,Christophe Fermé,Maria Gomes da Silva,Catherine Sebban,Andrew Lister,Jane Estell,Gustavo Milone,Anne Sonet,Myriam Mendila,Bertrand Coiffier,Hervé Tilly +29 more
TL;DR: 2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicular lymphoma significantly improves PFS.
Journal ArticleDOI
Report on the First International Workshop on interim-PET scan in lymphoma
TL;DR: The aim of the workshop was to reach a consensus on simple, reproducible criteria for interim-PET interpretation in Hodgkin lymphoma and diffuse large B-cell lymphoma, and to launch two or more international validation studies, in an attempt to validate these rules.